Orion Oyj Logo

Orion Oyj

Develops and manufactures human/vet pharma, APIs, and generics for global markets.

ORNAV | HE

Overview

Corporate Details

ISIN(s):
FI0009014377 (+1 more)
LEI:
74370029VAHCXDR7B745
Country:
Finland
Address:
Orionintie 1, FI-02200 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). With a history of over a century, the company focuses on 'building well-being' by translating scientific research into novel therapies and treatments. Orion's research and development efforts are primarily concentrated on specific therapeutic areas, including oncology and pain management. In addition to its portfolio of proprietary drugs, the company also produces generic products and self-care items. Its subsidiary, Fermion, is a key manufacturer of APIs for both Orion and external customers worldwide. Orion also engages in contract manufacturing and the development of diagnostic tests.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 11:00
Quarterly Report
Orion-konsernin osavuosikatsaus tammi-syyskuu 2025
Finnish 22.8 KB
2025-10-28 11:00
Quarterly Report
Orion Group Interim Report January-September 2025
English 22.5 KB
2025-10-24 08:00
Share Issue/Capital Change
49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-10-24 08:00
Share Issue/Capital Change
49,164 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-09-30 08:00
Major Shareholding Notification
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-30 08:00
Major Shareholding Notification
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-26 15:30
Major Shareholding Notification
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-26 15:30
Major Shareholding Notification
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-19 08:00
Share Issue/Capital Change
80 802 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-09-19 08:00
Share Issue/Capital Change
80,802 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-20 08:00
Share Issue/Capital Change
337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-08-20 08:00
Share Issue/Capital Change
337,000 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-08 08:30
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Juhani Kankaanpää
Finnish 4.9 KB
2025-08-08 08:30
Director's Dealing
Orion Corporation: Managers' transactions - Juhani Kankaanpää
English 4.8 KB
2025-08-04 15:10
Director's Dealing
Orion Oyj: Johtohenkilöiden liiketoimet - Satu Ahomäki
Finnish 3.5 KB

Automate Your Workflow. Get a real-time feed of all Orion Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orion Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orion Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America CLNN
Climb Bio, Inc. Logo
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America CLYM
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America COCP
Co-Diagnostics, Inc. Logo
Develops patented PCR solutions for accurate infectious disease diagnostics.
United States of America CODX
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America CGTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.